Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Genome-wide mutant fitness profiling identifies nutritional requirements for optimal growth of Yersinia pestis in deep tissue.

Palace SG, Proulx MK, Lu S, Baker RE, Goguen JD.

MBio. 2014 Aug 19;5(4). pii: e01385-14. doi: 10.1128/mBio.01385-14.

2.

Multiple roles of Myd88 in the immune response to the plague F1-V vaccine and in protection against an aerosol challenge of Yersinia pestis CO92 in mice.

Dankmeyer JL, Fast RL, Cote CK, Worsham PL, Fritz D, Fisher D, Kern SJ, Merkel T, Kirschning CJ, Amemiya K.

J Immunol Res. 2014;2014:341820. doi: 10.1155/2014/341820. Epub 2014 Jun 4.

3.

Opposing roles for interferon regulatory factor-3 (IRF-3) and type I interferon signaling during plague.

Patel AA, Lee-Lewis H, Hughes-Hanks J, Lewis CA, Anderson DM.

PLoS Pathog. 2012;8(7):e1002817. doi: 10.1371/journal.ppat.1002817. Epub 2012 Jul 26.

4.

Amino acid substitutions in LcrV at putative sites of interaction with Toll-like receptor 2 do not affect the virulence of Yersinia pestis.

Sun W, Curtiss R 3rd.

Microb Pathog. 2012 Nov-Dec;53(5-6):198-206. doi: 10.1016/j.micpath.2012.07.003. Epub 2012 Jul 24.

5.

Interleukin-10 induction is an important virulence function of the Yersinia pseudotuberculosis type III effector YopM.

McPhee JB, Mena P, Zhang Y, Bliska JB.

Infect Immun. 2012 Jul;80(7):2519-27. doi: 10.1128/IAI.06364-11. Epub 2012 Apr 30.

6.

What have we learned from brucellosis in the mouse model?

Grilló MJ, Blasco JM, Gorvel JP, Moriyón I, Moreno E.

Vet Res. 2012 Apr 13;43:29. doi: 10.1186/1297-9716-43-29. Review.

7.

Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.

Branger CG, Sun W, Torres-Escobar A, Perry R, Roland KL, Fetherston J, Curtiss R 3rd.

Vaccine. 2010 Dec 16;29(2):274-82. doi: 10.1016/j.vaccine.2010.10.033. Epub 2010 Oct 24.

8.

Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.

Boyer JL, Sofer-Podesta C, Ang J, Hackett NR, Chiuchiolo MJ, Senina S, Perlin D, Crystal RG.

Hum Gene Ther. 2010 Jul;21(7):891-901. doi: 10.1089/hum.2009.148.

9.

Bordetella evades the host immune system by inducing IL-10 through a type III effector, BopN.

Nagamatsu K, Kuwae A, Konaka T, Nagai S, Yoshida S, Eguchi M, Watanabe M, Mimuro H, Koyasu S, Abe A.

J Exp Med. 2009 Dec 21;206(13):3073-88. doi: 10.1084/jem.20090494. Epub 2009 Dec 14.

10.

Amino acid and structural variability of Yersinia pestis LcrV protein.

Anisimov AP, Dentovskaya SV, Panfertsev EA, Svetoch TE, Kopylov PKh, Segelke BW, Zemla A, Telepnev MV, Motin VL.

Infect Genet Evol. 2010 Jan;10(1):137-45. doi: 10.1016/j.meegid.2009.10.003. Epub 2009 Oct 14.

11.

Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica.

Branger CG, Torres-Escobar A, Sun W, Perry R, Fetherston J, Roland KL, Curtiss R 3rd.

Vaccine. 2009 Aug 27;27(39):5363-70. doi: 10.1016/j.vaccine.2009.06.078. Epub 2009 Jul 9.

12.

Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge.

Sofer-Podesta C, Ang J, Hackett NR, Senina S, Perlin D, Crystal RG, Boyer JL.

Infect Immun. 2009 Apr;77(4):1561-8. doi: 10.1128/IAI.00856-08. Epub 2009 Jan 5.

13.

Substrains of 129 mice are resistant to Yersinia pestis KIM5: implications for interleukin-10-deficient mice.

Turner JK, Xu JL, Tapping RI.

Infect Immun. 2009 Jan;77(1):367-73. doi: 10.1128/IAI.01057-08. Epub 2008 Oct 27.

14.

Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis.

Depaolo RW, Tang F, Kim I, Han M, Levin N, Ciletti N, Lin A, Anderson D, Schneewind O, Jabri B.

Cell Host Microbe. 2008 Oct 16;4(4):350-61. doi: 10.1016/j.chom.2008.09.004.

15.

Immune defense against pneumonic plague.

Smiley ST.

Immunol Rev. 2008 Oct;225:256-71. doi: 10.1111/j.1600-065X.2008.00674.x. Review.

16.

Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.

Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D, Ciletti NA, Schneewind O.

Infect Immun. 2008 Dec;76(12):5588-97. doi: 10.1128/IAI.00699-08. Epub 2008 Sep 15.

17.

Current challenges in the development of vaccines for pneumonic plague.

Smiley ST.

Expert Rev Vaccines. 2008 Mar;7(2):209-21. doi: 10.1586/14760584.7.2.209. Review.

18.

Interaction between Yersinia pestis and the host immune system.

Li B, Yang R.

Infect Immun. 2008 May;76(5):1804-11. doi: 10.1128/IAI.01517-07. Epub 2008 Feb 4. Review. No abstract available.

19.

Capsular antigen fraction 1 and Pla modulate the susceptibility of Yersinia pestis to pulmonary antimicrobial peptides such as cathelicidin.

Galván EM, Lasaro MA, Schifferli DM.

Infect Immun. 2008 Apr;76(4):1456-64. doi: 10.1128/IAI.01197-07. Epub 2008 Jan 28.

20.

Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.

Sha J, Agar SL, Baze WB, Olano JP, Fadl AA, Erova TE, Wang S, Foltz SM, Suarez G, Motin VL, Chauhan S, Klimpel GR, Peterson JW, Chopra AK.

Infect Immun. 2008 Apr;76(4):1390-409. doi: 10.1128/IAI.01529-07. Epub 2008 Jan 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk